Research programme: diabetes vaccine - AFFiRiS

Drug Profile

Research programme: diabetes vaccine - AFFiRiS

Latest Information Update: 08 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AFFiRiS
  • Class Peptide vaccines
  • Mechanism of Action Immunomodulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Research Type 2 diabetes mellitus
  • Discontinued Diabetes mellitus

Most Recent Events

  • 08 Sep 2016 Discontinued - Preclinical for Diabetes mellitus in Austria (Parenteral) (AFFiRis pipeline, September 2016)
  • 08 Sep 2016 Early research in Type-2 diabetes mellitus in Austria (Parenteral) before September 2016 (AFFiRis pipeline, September 2016)
  • 25 Jun 2014 Research programme: diabetes vaccine - AFFiRiS is available for licensing as of 25 Jun 2014.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top